Immunity of the Vaccine against Yellow Fever in patients taking medications that affect the immune system
Not Applicable
- Conditions
- nspecified rheumatoid arthritisM06.9
- Registration Number
- RBR-946bv5
- Lead Sponsor
- Centro de Pesquisas René Rachou- FIOCRUZ
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Be over 18 years of age; to present a diagnosis of Rheumatoid Arthritis; being in use of immunosuppressants; be accompanied at the University Hospital of Brasília; have previously been vaccinated against yellow fever
Exclusion Criteria
Pregnant women ; organic mental illness; carriers of other autoimmune diseases or neoplasms
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expected outcome 1:<br>A lower vaccine protection in the study group (rheumatoid arthritis using immunosuppressants) was verified by the antigen-specific B and T lymphocyte profile, analyzed by flow cytometry of the peripheral mononuclear cell culture;Expected outcome 2:<br>The study group (rheumatoid arthritis using immunosuppressants) has a lower amount of neutralizing antibodies, verified by the PRNT (plaque reduction neutralization test) method, in comparison to the control group
- Secondary Outcome Measures
Name Time Method ess vaccine protection in the study group (rheumatoid arthritis using immunosuppressive drugs) verified by the signature profile of intracytoplasmic cytokines, analyzed by flow cytometry of the peripheral mononuclear cell culture